Aimmune Therapeutics (AIMT) Misses Q4 EPS by 8c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q4 EPS of ($0.55), $0.08 worse than the analyst estimate of ($0.47).

Cash, cash equivalents, and investments totaled $282.5 million at December 31, 2016, compared to $199.8 million at December 31, 2015. The increase reflects the $145.0 million equity investment by Nestlé Health Science in November 2016, partially offset by cash used in operations.

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics